Coya: Coya Therapeutics, Inc.: Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025
Principal Investigator Alireza Faridar, M.D. to provide overview of data for the investigator-initiated "Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients with Mild to Moderate Alzheimer...
Read full article »
Coya is a Texas-based clinical-stage biotechnology firm that researches and develops T-cell-modulating therapies for neurodegenerative, autoimmune, and metabolic diseases.
Read more